DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Aldoril (Methyldopa / Chlorothiazide) - Summary

 
 



WARNING

This fixed combination drug is not indicated for initial therapy of hypertension. Hypertension requires therapy titrated to the individual patient. If the fixed combination represents the dosage so determined, its use may be more convenient in patient management. The treatment of hypertension is not static, but must be re-evaluated as conditions in each patient warrant.

 

ALDORIL SUMMARY

TABLETS
ALDORIL ®
(METHYLDOPA-HYDROCHLOROTHIAZIDE)

ALDORIL (Methyldopa-Hydrochlorothiazide) combines two antihypertensives: methyldopa and hydrochlorothiazide.

ALDORIL is indicated for the treatment of hypertension.


See all Aldoril indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Aldoril (Methyldopa / Chlorothiazide)

Diet Effects Debated in Intracranial Hypertension
Source: Medscape Ophthalmology Headlines [2015.02.27]
Does acetazolamide improve symptoms of intracranial hypertension by lowering cerebrospinal fluid pressure, or does it work by increasing weight loss?
Medscape Medical News

Pulmonary Hypertension
Source: MedicineNet Fainting Specialty [2015.02.19]
Title: Pulmonary Hypertension
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 2/19/2015 12:00:00 AM

"Danger" molecule may be new therapeutic target for male hypertension
Source: Hypertension News From Medical News Today [2015.02.17]
Higher levels of a "danger" molecule may be one reason males tend to become hypertensive earlier and more severely than females, scientists say.

Pregnancy associated hypertension linked to an increased frequency of subsequent hypertension and metabolic syndrome
Source: Hypertension News From Medical News Today [2015.02.04]
In a study to be presented on Feb. 5 in an oral concurrent session at 2:45 p.m.

New hypertension guidelines could save lives and money
Source: Hypertension News From Medical News Today [2015.01.30]
Increased treatment of severe hypertension particularly cost-effectiveFull implementation of new hypertension guidelines could prevent 56,000 cardiovascular disease events (mostly heart attacks...

more news >>

Published Studies Related to Aldoril (Methyldopa / Chlorothiazide)

Combination of a thiazide, a vasodilator and reserpine compared with methyldopa plus hydrochlorothiazide in the treatment of hypertension in Zimbabwe. [1990.03.03]
Brinerdin (Sandoz), a combination of a diuretic (clopamide 5 mg), a vasodilator (dihydro-ergocristine 0.5 mg) and reserpine (0.1 mg) (CDR) was compared with methyldopa (MD) plus hydrochlorothiazide (HCT) for antihypertensive effect, adverse reactions, compliance and patient preference in an open cross-over trial...

Evaluation of the efficacy and safety of enalapril plus hydrochlorothiazide plus methyldopa vs standard triple therapy in the treatment of moderate to severe hypertension: results from a multicentre study. [1990.02]
We report the results of a randomized, double-blind, parallel group multicentre study in 120 patients with moderate to severe hypertension, comparing two different types of antihypertensive treatment: a) the standard 'triple therapy' with hydrochlorothiazide, propranolol and hydralazine, and b) the combination of an ACE inhibitor, enalapril with hydrochlorothiazide (HCTZ) and methyldopa...

Oral enalapril-hydrochlorothiazide-methyldopa as first line treatment for severe hypertension in Nigerians. [2004.01]
A combination of low-dose oral enalapril, methyldopa and hydrochlorothiazide was evaluated in the acute treatment of severe hypertension. Blood pressure moved from an average 210/120 mmHg at the onset to an average 135/79 mmHg within 24 hours, without any significant side effects and at about half the cost of commonly used parenteral hydralazine..

more studies >>


Page last updated: 2015-02-27

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015